Baxter International’s CDMO unit plans a $100 million expansion to its sterile fill-finish manufacturing facility in western Germany, the company announced last week. The investment adds to a multibillion-dollar investment spree among manufacturers worldwide.

In related news, Samsung Biologics has bought land in Incheon, South Korea, where it plans a $259 million genetic medicines facility, the Korea Herald reported in early November.

Shanghai-based generics company Fosun has made a “non-binding proposal” to buy India’s Gland Pharma, Reuters reported on Monday.

Backed by investment firm KKR, Gland Pharma is estimated to be worth as much as $1.5 billion. Gland Pharma’s has reportedly also caught the attention of Baxter and Advent International, which are similarly interested in bidding on the sterile injectables manufacturer.